-
All Resources
(choose a category)
-
All Resources
-
selected
Evidence
Evidence, advice, guidance and standards
-
Improvement
Improvement and implementation support
-
selected
Scrutiny
Assurance, scrutiny, measurement and reporting
-
-
Healthcare Area
- Blood and immune system
- Cancer
- Cardiovascular system
- Dermatology
- Digestive system
- Ear, nose and throat
- Endocrine, nutritional and metabolic
- Eye
- Genitourinary system
- Infectious disease
- Injuries, accidents and wounds
- Mental and behavioural disorders
- Mouth and dental
- Musculoskeletal system
- Nervous system
- Obstetrics and gynaecology
- Respiratory system
-
Resource Type
- NICE Guidance
- Programme
- Year
- prev
- Page 4 of 2
20 results found filtered by Evidence Remove Evidence Filter Scrutiny Remove Scrutiny Filter 2007 Remove 2007 Filter 2010 Remove 2010 Filter 2009 Remove 2009 Filter NICE Guidance Remove NICE Guidance Filter Clear Search
-
Nice (Multiple) Technology Appraisal Guidance No: 131 and No: 132
- Published
- 19 December 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
- Published
- 28 November 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 133 – Omalizumab for severe persistent allergic asthma
- Published
- 28 November 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 129: Bortezomib monotherapy for relapsed multiple myeloma
- Published
- 24 October 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 128 Stapled Haemorrhoidopexy for the treatment of haemorrhoids128
- Published
- 26 September 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 124: Pemetrexed for the treatment of non-small cell lung cancer
- Published
- 22 August 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance 125: Adalimumab for the treatment of psoriatic arthritis
- Published
- 22 August 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance 126: Ritixumab for the treatment of rheumatoid arthritis
- Published
- 22 August 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance 127: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosi
- Published
- 22 August 2007
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 122: Alteplase for the treatment of acute ischaemic stroke
- Published
- 27 June 2007
- Cycle of Improvement
- Evidence